Professional Documents
Culture Documents
S0091-6749(16)30800-4
DOI:
10.1016/j.jaci.2016.06.054
Reference:
YMAI 12290
To appear in:
Please cite this article as: Fergeson JE, Patel S, Lockey RF, Acute Asthma, Prognosis and Treatment,
Journal of Allergy and Clinical Immunology (2016), doi: 10.1016/j.jaci.2016.06.054.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT
Authors:
Affiliations:
SC
RI
PT
12
13
14
15
16
17
18
TE
D
11
Jennifer E. Fergeson DO
EP
10
Corresponding author:
AC
C
M
AN
U
Email - jfergeso@health.usf.edu
ACCEPTED MANUSCRIPT
Abstract
20
Asthma affects about 300 million people globally and accounts for 1 in every 250 deaths
21
in the world. Approximately 12 million people in the United States each year experience
22
23
asthma should be differentiated from poor asthma control. In acute asthma, patients will
24
25
contrast, poor asthma control typically presents with a diurnal variability in airflow and is
26
a characteristic that is usually not seen during an acute exacerbation. The history should
27
28
near-fatal asthma, and whether the patient has experienced multiple emergency room
29
30
31
important to ensure that the patient understands that asthma is mostly a chronic disease
32
33
34
regimens. This article is a structured review of the available literature regarding the
35
36
Key word: Asthma flare; Acute asthma; Asthma attack; Wheezing; Acute asthma
37
38
Abbreviations:
39
40
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
19
42
43
44
45
46
47
48
AE Adverse events
49
50
53
54
55
M
AN
U
TE
D
EP
52
AC
C
51
SC
41
RI
PT
ACCEPTED MANUSCRIPT
56
57
ACCEPTED MANUSCRIPT
Introduction
59
Asthma exacerbations are avoidable with appropriate, regular therapy and patient
60
education. Despite this, asthma affects about 300 million people globally, and accounts
61
for 1 in every 250 deaths [1]. In the United States alone, approximately 12 million people
62
each year experience an acute exacerbation of their asthma, a quarter of which require
63
hospitalization [2]. In Europe, approximately 30 million people have asthma, and 15,000
64
people die yearly from this disease [4]. This manuscript is about acute asthma, its
65
66
Various clinical symptoms and signs may assist the clinician in determining the severity
67
of acute asthma (Figure 1) [2,10]. To prevent severe exacerbations of asthma, the goals
68
69
1. Recognition of patients who are at a greater risk for near-fatal or fatal asthma.
70
71
3. Provision of an individual action plan for the patient to manage the exacerbation and to
72
73
74
reflux disease (GERD), obstructive sleep apnea (OSA), chronic obstructive respiratory
75
disease (COPD), vocal cord dysfunction (VCD) and atopic dermatitis [3, 6-9].
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
58
76
77
ACCEPTED MANUSCRIPT
Physical examination
79
Clinical estimates of severity based on an interview and a physical examination can result
80
81
82
Symptoms of severe asthma include chest tightness, cough (with or without sputum),
83
sensation of air hunger, inability to lie flat, insomnia and severe fatigue. The signs of
84
severe asthma include use of accessory muscles of respiration, hyperinflation of the chest,
85
86
inability to complete sentences and difficulty in lying down. Altered mental status, with
87
88
hospitalization are required. A detailed examination should include examining for signs
89
90
91
supraclavicular areas of the chest wall. Special attention should be paid to the patient's
92
blood pressure, pulse and respiratory rate. Tachycardia and tachypnea may be suggestive
93
94
respiratory arrest. Pulsus paradoxus is often present and may correlate with the severity
95
96
97
98
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
78
ACCEPTED MANUSCRIPT
99
101
102
Risk factors for asthma exacerbations can be identified from the clinical history. The
103
patient interview should include questions about recent events including [2,5]:
SC
RI
PT
100
1.
105
2.
106
3.
107
4.
M
AN
U
104
109
Major risk factors for near-fatal and fatal asthma are recognized, and their presence
110
makes early recognition and treatment of an asthma exacerbation essential. The history
111
should include a review of previous episodes of near-fatal asthma and whether the patient
112
113
requiring admission to an intensive care unit, involving respiratory failure, intubation and
114
115
allergic symptoms should be obtained. For example, Nelson et al. identified a trigger for
116
severe asthma is allergy to the mold Alternaria and several dust mite species [5,10].
117
Adherence with medical treatments should be reviewed; poor adherence with prescribed
118
therapies is a major risk factor. Inadequate therapy may include excessive use of 2-
AC
C
EP
TE
D
108
ACCEPTED MANUSCRIPT
120
121
(OCS) suggests that the patient is at greater risk for a severe exacerbation. Lack of a
122
written asthma action plan is another risk factor. Limited access of the patient to
123
appropriate health care and lack of education about appropriate management strategies
124
are additional risk factors. Socioeconomic factors associated with severe asthma
125
126
city environments. Certain ethnic groups within a population may have a higher
127
128
Comorbidities, such as chronic lung, psychiatric, and cardiovascular diseases are other
129
130
131
132
obstruction and response to therapy. A peak expiratory flow (PEF) rate provides a simple,
133
quick, and cost-effective assessment of the severity of airflow obstruction. Patients can be
134
supplied with an inexpensive PEF meter and taught to perform measurements at home to
135
detect deterioration of their asthma. An individual management plan will be based upon
136
the personal best PEF value. Predetermined PEF values can be set at which time the
137
patient is alerted to the degree of severity of symptoms and can institute appropriate
138
therapy and/or consult their physician (Figure 2). In non-acute settings, assessment of
139
PEF and spirometry before and after administration of a bronchodilator can indicate the
140
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
119
ACCEPTED MANUSCRIPT
therapy. PEF values of 50-79% of predicted or personal best signify the need for
142
immediate treatment with an inhaled short acting beta agonist (SABA). Values below
143
50% indicate the need for immediate medical care. Values below 35% indicate a possible
144
severe life threatening episode. This treatment should be administered with a SABA via
145
nebulizer or metered dose inhaler (MDI). SABA dose, response, and further
146
147
The forced expiratory volume in one second (FEV1) is measured by spirometry to assess
148
the volume of air exhaled over one second and is the most sensitive test for airflow
149
obstruction. The FEV1 is less variable than PEF and is independent of effort once a
150
moderate effort has been made by the patient. Post bronchodilator reversibility should be
151
assessed and an increase in FEV1 > 12% and > 200 ml is diagnostic of asthma [2, 12].
152
Most patients do not require laboratory testing for the diagnosis of acute asthma. If
153
laboratory studies are obtained, they must not delay asthma treatment. Laboratory studies
154
may assist in detecting other comorbid conditions that complicate asthma treatment, such
155
156
peptide (BNP) and a 2-D transthoracic echocardiogram aid in the diagnosis of congestive
157
heart failure. For patients taking diuretics who have co-morbid cardiovascular disease,
158
serum electrolytes may be useful as frequent SABA administration can cause transient
159
160
and monitoring of cardiac rhythm are appropriate in patients older than 50 years of age
161
and in those with comorbid cardiovascular disease or COPD. A complete blood cell
162
count (CBC) may be useful in patients with fever or purulent sputum; however, modest
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
141
ACCEPTED MANUSCRIPT
164
165
for patients taking theophylline due to its narrow therapeutic window [12].
166
Chest radiographs are not usually necessary for the diagnosis of acute asthma if the
167
examination of the chest reveals no abnormal findings other than the expected clinical
168
169
170
171
[12].
172
Arterial blood gas (ABG) analysis should be considered in patients who are critically ill
173
and have oxygen saturations of < 92% or an FEV1 < 30% who do not respond to
174
intensive conventional treatment. Proper interpretation of the pH, PaO2, and PaCO2 may
175
help further assess the severity of an acute exacerbation of asthma (Figure 1). For
176
example, a breathless asthmatic presenting with a PaCO2 > 45 mmHg indicates a life
177
threatening attack and the need for transfer to a medical intensive care unit for further
178
care. Less than 10% of asthmatic patients presenting to the emergency department have
179
arterial oxygen values < 50 mmHg and carbon dioxide levels > 45 mmHg [11, 15]. Lactic
180
acidosis is common in severe acute asthma. However, elevated lactic acid levels are also
181
182
Venous blood gases (VBG) have been evaluated as a substitute for arterial measurements
183
since venous blood is easier to obtain. However, The Expert Panel Report 3 (EPR3) does
184
not recommend substituting venous PCO2 (PvCO2) for ABG. Arteriovenous correlation
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
163
ACCEPTED MANUSCRIPT
for PCO2 is poor, and therefore PvCO2 cannot be relied upon as an absolute
186
representation of PaCO2. However, a normal PvCO2 has a good negative predictive value
187
for a normal PaCO2. Therefore, it may be used as a screening test to exclude hypercapneic
188
189
Treatment
190
Treatment is based not only on assessment of lung function parameters but on clinical
191
192
193
194
and to an adjustment in ICS, whereas the infected patient is more likely to require a
195
systemic corticosteroid (SCS) [4]. A patient who is over-using short acting 2-agonists
196
may be refractory to nebulized 2-agonists and will usually require a SCS. Physician
197
198
199
There are various national and international guidelines available for the diagnosis and
200
management of acute asthma. In particular, the EPR3 guidelines are referenced in this
201
202
and provides the best evidence for clinical practice guidelines. EPR3 recommended
203
treatment choices in order of introduction in the acute setting are listed below and
204
depicted in Figure 3. Treatment options and their recommended doses are listed in Figure
205
4.
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
185
10
ACCEPTED MANUSCRIPT
206
208
209
210
4. Oxygen
RI
PT
207
Some patients may not respond to primary treatment and show signs of worsening
212
asthma. Other treatments are sometimes used in these patients and may include:
M
AN
U
SC
211
214
215
216
217
TE
D
213
Short-acting 2-agonists
219
EPR 3 guidelines recommend the use of only selective SABAs in high doses (i.e.
220
221
patients. Initial treatment should begin with albuterol, either administered by MDI with a
222
223
Treatment should be continued until the patient has stabilized or a decision to hospitalize
224
is made. Studies show that the use of either MDI or nebulizer for delivery of inhaled
225
AC
C
EP
218
11
ACCEPTED MANUSCRIPT
who are unable to cooperate using an MDI because of the severity of acute asthma, age or
227
228
asthma based on evidence of reduced admissions and improved pulmonary function [12,
229
19-21].
230
231
232
comparable efficacy and safety. However, the efficacy of continuous nebulization has
233
not been evaluated. Continuous administration of albuterol via large volume nebulizers
234
235
236
237
238
monitored for signs of adrenergic toxicity. At this time, there is no proven advantage of
239
240
241
Ipratropium bromide
242
243
244
receptor, thus relaxing smooth muscle in large central airways. It is not a first-line
245
therapy but can be added in severe asthma particularly when albuterol is not optimally
246
beneficial. It can be given with albuterol or levalbuterol and may be used for up to 3
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
226
12
ACCEPTED MANUSCRIPT
hours in the initial management of acute asthma. There is increasing support for adding
248
249
children. Studies indicate that combined therapy reduces the risk of hospital admission
250
251
252
253
treatment of mild asthma exacerbations with OCS. However, due to limited data, high-
254
dose ICS should be reserved for patients with mild asthma and those who refuse or
255
cannot tolerate OCS, e.g., have brittle diabetes or experience major side effects from
256
SCS. Guidelines recommend at least quadrupling the recommended dose of ICS. For
257
example, a top recommended maintenance dose of fluticasone can be increased from 220
258
259
increased from 160 mcg, 2 puffs, 2x/day to 160 mcg, 4 puffs, 4x/day [2]. Treatment
260
should be started before the patient becomes too ill to manage their disease at home.
261
Inhaled therapy reduces the risk of unwanted side effects associated with SCS treatment
262
263
metabolism and other organ systems. ICS are less likely to be effective in patients with
264
upper respiratory tract infections or those who are over-utilizing 2-agonists. OCS, with
265
instructions for its use, should be prescribed as a backup treatment regimen and the
266
patient and/or family understand when to start it. They should also have immediate access
267
268
resolved [23-25]. When an ICS is prescribed for mild asthma and is not effective, OCS
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
247
13
ACCEPTED MANUSCRIPT
270
psychosis, hypertension, and other side effects should be concomitantly treated until the
271
272
Short courses of OCS are effective to establish control of flare-ups of asthma or during a
273
274
Treatment should be continued until the patient is well or achieves a PEF of 80% of
275
276
277
not necessary to taper OCS after three weeks or less of treatment, but when used for
278
longer than 3 weeks, it is advisable to taper the medication over one to two weeks to
279
280
281
282
There are no substantial data to indicate that SCS are immediately helpful in the acute
283
asthma setting because the onset of action does not occur for hours after administration.
284
However, SCS are the best medications available to reduce airway inflammation and
285
should be used immediately until the attack has abated as evidenced based on their
286
clinical response or by the PEF and FEV1 returning to near baseline levels [12].
287
288
treatment of acute asthma; however, there is no evidence that these routes have a more
289
rapid onset of action or are more effective than is oral administration [12].
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
269
14
ACCEPTED MANUSCRIPT
291
After discharge from the hospital, approximately 10-20% of patients treated for acute
292
asthma will relapse within 2 weeks. This may be due to unresolved inflammation
293
associated with asthma. As a result, EPR3 encourages treatment with OCS following
294
emergency room discharge. ICS therapy should be resumed or short/long term ICS
295
therapy initiated to reduce the chances of a relapse. When the patients asthma is stable,
296
the ICS should be incrementally reduced to maintain an asymptomatic state and a PEF at
297
a personal best level. A combination of long acting 2-agonist and an ICS can be
298
299
Magnesium sulfate
300
301
302
patients presenting with severe life-threatening asthma exacerbations (FEV1 < 25%
303
predicted) and those who remain in the severe category after 1 hour of intensive
304
305
306
307
308
both children and adults who exhibit severe life-threatening exacerbations and those who
309
remain in the severe category after one hour of intensive conventional therapy [12,26].
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
290
15
ACCEPTED MANUSCRIPT
Hospitalization
311
312
313
Hydration in young infants and children may be essential as these patients are at
314
increased risk for dehydration due to poor oral intake and an increased respiratory rate.
315
316
better tolerated to maintain a SaO2 > 90%. In pregnant patients and those with underlying
317
cardiac disease, a SaO2 > 95% is recommended. The patient should be monitored
318
continuously with pulse oximetry and telemetry. Blood gases should be obtained until
319
the patient is stable. The patient should be treated with continuous nebulized albuterol or
320
321
tract infections are more common in acute asthma exacerbation and therefore antibiotics
322
should be reserved for patients who present with evidence of a co-existing bacterial
323
infection, i.e., pneumonia, bronchitis, and sinusitis. EPR3 does not recommend the use of
324
325
326
327
The use of non-invasive positive pressure ventilation (NPPV) in the treatment of severe
328
acute asthma can be tried in patients who are at increased risk of respiratory failure, can
329
safely cooperate with NPPV treatment, and do not require emergent intubation [12]. A
330
review article by the Cochrane Reviews Group carried out a search of randomized
331
controlled trials of adults with severe acute asthma that presented to the emergency
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
310
16
ACCEPTED MANUSCRIPT
department or were admitted to the hospital. Studies in the article were included if the
333
intervention was usual medical care for the management of severe acute asthma plus
334
NPPV compared to usual medical care alone. All six studies that were reviewed
335
concluded that NPPV may be beneficial. The results did not show a clear benefit for
336
NPPV use for its primary outcomes, i.e. mortality rate and tracheal intubation. However,
337
NPPV use did show favorable outcomes in many secondary objectives, such as number
338
of hospital admissions, length of ICU stay, length of hospital stay, and improvement in
339
lung function parameters (PEF, FVC, FEV1, and FEF25-75). Study quality of the evidence
340
was an issue in this review as all six studies included had at least one identifiable source
341
of unclear or high risk of bias. As only six studies were reviewed by the Cochrane
342
343
Randomized controlled trials with a large sample size, good methodological design, and
344
minimizing the risk of bias are needed to answer the question of the use of NPPV in acute
345
asthma [30].
346
The EPR3 recommends that intubation should not be delayed in a patient once it is
347
deemed necessary. Patients that present with apnea or coma should be intubated
348
349
strongly suggest the need for mechanical ventilation. Intubation is difficult in patients
350
with acute asthma and should be performed, where possible, by a physician who has
351
352
353
354
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
332
17
ACCEPTED MANUSCRIPT
356
high ventilator pressures should be avoided where possible, due to their associated risks
357
358
ventilator strategy because this provides adequate oxygenation and ventilation without
359
the risks of barotrauma associated with high ventilator pressures. SABA should be
360
361
362
Conclusion
363
Asthma affects approximately 300 million people in the world and accounts for 1 in
364
every 250 deaths. The World Health Organization recognizes asthma as a major global
365
health issue affecting all age groups in all countries. All patients presenting with an
366
367
368
should recognize the symptoms, signs, and risk factors (including comorbidities) for
369
370
administration, SABA, and SCS. If the patient cannot tolerate SCS, high dose ICS may
371
be initiated in selected patients. For patients that do not respond to primary treatment and
372
show worsening signs of ventilation, secondary treatment options may be utilized. These
373
374
375
376
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
355
18
ACCEPTED MANUSCRIPT
inhaler techniques for all prescribed medications and reinforce correct technique. Patients
378
should be referred for a follow-up appointment with a primary care physician or asthma
379
382
383
384
385
386
387
388
389
SC
381
Key points
M
AN
U
380
RI
PT
377
TE
D
390
Figure 1: Acute asthma severity: clinical signs and symptoms. Originally published
392
393
394
395
396
397
398
AC
C
EP
391
19
ACCEPTED MANUSCRIPT
400
metered dose inhaler; PCO2 = partial pressure of carbon dioxide; PEF = peak expiratory
401
402
403
404
405
406
407
Notes:
SC
M
AN
U
408
RI
PT
399
410
411
TE
D
409
413
courses of less than 1 week, there is no need to taper the dose. For slightly longer
414
416
AC
C
415
EP
412
417
418
419
420
20
ACCEPTED MANUSCRIPT
421
EP
TE
D
M
AN
U
SC
RI
PT
1. Masoli, M. (2004, February 1). The global burden of asthma: Executive summary
of the GINA Dissemination Committee Report. Allergy, 469-478.
2. Camargo, C.A., Rowe, B.H. Asthma Exacerbations. Barnes, P.J., Drazen, J.,
Rennard, S., Thomson, N. (Eds.), Asthma and COPD: Basic Mechanisms and
Clinical Management, 2nd ed. San Diego, CA: Elsevier Ltd; 2009. p. 775-791.
3. Lockey RF, Ledford DK, in collaboration with the World Allergy Organization
(eds): Asthma, Comorbidities, Co-Existing Conditions, and Differential
Diagnoses. Oxford University Press, New York, NY, 2014, p, 231-367.
4. The Journal of Allergy and Clinical Immunology: In Practice. Asthma Phenotypes.
November - December 2014; 2(6): 645-826.
5. Global Initiative For Asthma (GINA) Website. http://www.ginasthma.com/.
(Accessed on 3/15/15)
6. Holguin F, Bleecker E, Busse W, Calhoun W, et al. Obesity and asthma: An
association modified by age of asthma onset. J Allergy Clin Immunol 2011;
127(6): 1486-1493.e2.
7. Ledford DK, Lockey RF. Asthma and comorbidities. Curr Opi Allergy Clin
Immunol 2013; 13: 78-86.
8. Blake K, Teague WG. Gastroesophageal reflux disease and childhood asthma.
Curr Opin Pulm Med 2013; 19:24-9.
9. Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for
asthma in adults and children. Cochrane Database Syst Rev 2003; 1: Art. No.:
CD001496.
10. Nelson R, DiNicolo R, Fernndez-Caldas E, Seleznik MJ, Lockey RF, Good R.
Allergen-specific IgE levels and mite allergen exposure in children with acute
asthma first seen in an emergency department and in nonasthmatic control
subjects. J Allergy Clin Immunol 1996; 98: 258-263.
11. Patel M, Pilcher J, Reddel H, Qi V. Predictors of severe exacerbations, poor
asthma control, and Beta-agonist overuse for patients with asthma. J Allergy Clin
Immunol 2014; 2(6); 751-758.e1.
12. Camargo, C.A., Rachelefsky, G., and Schatz, M. Managing Asthma
Exacerbations in the Emergency Department: Summary of the National Asthma
Education and Prevention Program Expert Panel Report 3 Guidelines for the
Management of Asthma Exacerbations. Proceedings of the American Thoracic
Society 2009; Vol 6, No 4: 357-366.
13. Hasegawa K, Sullivan A, Tsugawa Y, Turner, S. Comparison of US emergency
department acute asthma care quality: 1997-2001 and 2011-2012. J Allergy Clin
Immunol 2014; 135(1): 73-80.e7.
14. Waseem M, Leber M, Wasserman E, Sullivan A, et al. Factors associated with
concordance with the non-level-A guideline recommendations for emergency
department patients with acute asthma. J Allergy Clin Immunol 2015; 3(4): 618620.e2.
15. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British
guideline on the management of asthma. Thorax 2014; 69 Suppl1:1.
16. GJ, R. Elevated plasma lactate level associated with high dose inhaled albuterol
therapy in acute severe asthma. Emergency Med 2005; 404-408.
AC
C
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
References
21
ACCEPTED MANUSCRIPT
EP
TE
D
M
AN
U
SC
RI
PT
17. Bloom BM, Grundlingh J, Bestwick JP, Harris T. The role of venous blood gas in
the emergency department: a systematic review and meta-analysis. Eur J Emerg
Med 2014; 21:81.
18. Goodacre S, Braburn M, Cohen J, et al. Prediction of unsuccessful treatment in
patients with severe asthma. Emerg Med J 2014; 31: e40.
19. Camargo CA Jr., Spooner CH, Rowe BH. Continuous versus intermittent betaagonists for acute asthma. Cochrane Database Syst Rev (4): CD0011115, 2003.
20. Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulizers for
beta-agonist treatment of acute asthma. Cochrane Database System Rev(2):
CD000052, 2006.
21. Hasagawa K, Sullivan H, Hirashima E, et al. A multicenter observational study of
US adults with acute asthma: Who are the frequent users of the emergency
department. J Allergy Clin Immunol 2014; 2(6): 733-740.e3.
22. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children
and adults with acute asthma: a systematic review with meta-analysis. Thorax
2005; 60:740.
23. Oborne J, Mortimer K, Hubbard RB, et al. Quadrupling the dose of inhaled
corticosteroid to prevent asthma exacerbations: a randomized, double-blind,
placebo-controlled, parallel-group clinical trial. Am J Respir Crit Care Med 2009;
180:598.
24. Beckhaus AA, Riutort MC, Castro-Rodriguez JA. Inhaled versus systemic
corticosteroids for acute asthma in children. A systematic review. Pediatr
Pulmonol 2014; 49: 326-34.
25. Krishnan J, Nowak R, Davis S, Schatz M. Anti-inflammatory treatment after
discharge home from the emergency department in adults with acute asthma. J
Allergy Clin Immunol 2009; 124(2): S29-S34
26. Chaudry RQ, Weinstein ME, Petrova A. Efficacy of inhaled compared to oral
corticosteroids for acute asthma exacerbation in children. J Allergy Clin Immunol.
2010: 125 (2); AB69.
27. Thomas AO, Lemanske RF Jr, Jackson DJ. Infections and their role in childhood
asthma inception. Pediatr Allergy Immunol 2014; 25: 122-8.
28. Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P,
Bauman A, Hensley MJ, Walters EH. (2003). Self management education and
regular practitioner review for adults with asthma. The Cochrane Library 1:
CD001117.
29. Kang MG, Kim JY, Jung JW, Song JW, Cho SH, Min KU, et al. Lost to follow
up in asthmatics does not mean treatment failure: causes and clinical outcomes of
non-adherence to outpatient treatment in adult asthma. Allergy Asthma Immunol
Res 2013; 5:357-64.
30. Lim WJ, Mohammed Akram R, Carson KV, Mysore S, Labiszewski NA,
Wedzicha JA, Rowe BH, Smith BJ. Non-invasive positive pressure ventilation for
treatment of respiratory failure due to severe acute exacerbations of asthma.
Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD004360.
DOI: 10.1002/14651858.CD004360.pub4.
AC
C
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
22
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
M
AN
U
SC
RI
PT
ACCEPTED MANUSCRIPT
ACCEPTED MANUSCRIPT
Please wait...
If this message is not eventually replaced by the proper contents of the document, your PDF
viewer may not be able to display this type of document.
RI
PT
You can upgrade to the latest version of Adobe Reader for Windows, Mac, or Linux by
visiting http://www.adobe.com/go/reader_download.
For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.
AC
C
EP
TE
D
M
AN
U
SC
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark
of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other
countries.
ACCEPTED MANUSCRIPT
SC
RI
PT
M
AN
U
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and
Policies of the Accreditation Council for Continuing Medical Education (ACCME) by the
American Academy of Allergy, Asthma and Immunology (AAAAI). The AAAAI is accredited
by the ACCME to provide continuing medical education for physicians.
TE
D
Designation Statement
The American Academy of Allergy, Asthma and Immunology designates this educational
activity for 3.0 AMA PRA Category 1 Credits per review, with a maximum of 15.0 credits per
calendar year. Physicians should only claim credit commensurate with the extent of their
participation in the activity.
EP
Target Audience
This activity is intended for board-certified physicians and researchers in the fields of allergy and
immunology.
AC
C
Overall Purpose/Goal
The purpose of this activity is to affirm or modify knowledge, competence, or performance as a
result of reading the manuscript.
DESIGN COMMITTEE:
ACCEPTED MANUSCRIPT
and Speaker; GA2LEN, Global Allergy And Asthma European Network (Ongoing): Ex-com
Member World Immune Regulation Meetings (Ongoing): Chair, Organizer.
SC
RI
PT
M
AN
U
EP
TE
D
AC
C
ACCEPTED MANUSCRIPT
RI
PT
SC
M
AN
U
EP
TE
D
AC
C
Hirohisa Saito, MD PhD FAAAAI: Employer: National Research Institute for Child Health &
Development (Deputy Director of the Research Institute) Competing Relationships: Speaker:
Teijin Pharma Ltd, Shiseido Co.,Ltd., MSD (Merck Sharp and Dohme) K.K., Ono
Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Pfizer Japan Inc., Kyowa Hakko Kirin, Kyorin
Pharmaceutical, Daiichi Sankyo.
Stanley Szefler, MD FAAAI: Employer: University of Colorado Denver School of Medicine
(Professor of Pediatrics; Head, Pediatric Asthma Research) Competing Relationships: Advisory
Board: Aerocrine, Boehringer-Ingelheim, Novartis, Roche, Glaxo Smith Kline. NIH:NHLBI
(Ongoing): Research Grant: AsthmaNet, NIH:NIEHS/EPA (Ongoing): Research Grant:
Childhood Health and Environmental Center Grant, Colorado Public Health Department
(Ongoing): Research Grant, NIH:NIAID (Ongoing): Research Grant: Inner City Asthma
Consortium. Organizational Interests: AAAAI (Ongoing): Fellow; Deputy Editor For Journal
ACCEPTED MANUSCRIPT
RI
PT
SC
AC
C
EP
TE
D
M
AN
U
FACULTY DISCLOSURES
Please refer to the opening pages of the assigned manuscript for the authors relevant funding and
employment information.